DREADDs
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
Clozapine (HB1607)
Description:Prototypic, atypical antipsychotic, binds to both serotonin and dopamine receptors
Purity:>99%
- Description:
Water soluble prototypic, atypical antipsychotic. Binds to both serotonin and dopamine receptors.
Purity:>98%
-
Clozapine N-oxide (CNO) (freebase) (HB1807)
Description:Prototypical DREADD activator. Clozapine metabolite.
Purity:>98%
- Description:
Dihydrochloride salt of CNO - the prototypical DREADD activator
Purity:>98%
-
Compound 112254 hydrochloride (HB3847)
Description:Adiponectin receptor (AdipoR) agonist
Purity:>98%
-
CP 94253 dihydrochloride (HB1671)
Description:Potent, selective 5-HT1B receptor agonist
Purity:>98%
-
-
-
Cyclopamine (HB2965)
Description:Smo and hedgehog (Hh) signaling inhibitor. Also depletes stem like cancer cells and induces hESCs into endocrine cells.
Purity:>98%
